Effects of Femara and Tamoxifen on Proliferation of FM3A Cells in Culture

  • Topcul, Mehmet (Department of Biology, Faculty of Science, Istanbul University) ;
  • Topcul, Funda (Republic of Turkey Ministry of National Education IDMIB Leather Vocational High School) ;
  • Cetin, Idil (Department of Radiobiology, Institute of Science, Istanbul University)
  • Published : 2013.05.30


In this study, antiproliferative effects of the selective estrogen receptor modulator Tamoxifen and the aromatase inhibitor letrozole (Femara) were evaluated and compared using the FM3A cell line, originating from a C3H mouse mammary carcinoma and positive in terms of estrogen receptor (ER) expression. Cell kinetic parameters including labelling index, mitotic index and labelling index were assessed after exposure of the. FM3A cell line to $0.001{\mu}g/ml$ of Tamoxifen and $0.25{\mu}g/ml$ of Femara for 4, 8, 16 and 32 h for all parameters. The results showed that cell growth was inhibited by both agents. There was a significant decrease in labelling index and mitotic index and significant increase in apoptotic index for all experimental groups. The differences between control and all experimental groups were statistically significant (p<0.001) for all applications.


  1. Asselin-Labat M-L, Vaillant F, Sheridan JM, et al (2010). Control of mammary stem cell function by steroid hormone signalling. Nature, 465, 798-802.
  2. Azria D, Larbouret C, Cunat S, et al (2005). Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res, 7, 156-63.
  3. Bai Z, Gus R (2009). Breast cancer, estrogen receptor and ligands. Arch Pharm Chem Life Sci, 342, 133-49.
  4. Baum M (1999). Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocrine-Related Cancer, 6, 231-4.
  5. Baum M, Buzdar AU, Cuzick J, et al (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet, 359, 2131-9.
  6. Bedi KS, Goldstein DJ (1976). apparent anomalies in nuclear feulgen-DNA contents. J Cell Bio, 71, 68-88.
  7. Buzdar AU (2003). Advances in endocrine treatments for postmenopeusal women with metastatic and early breast cancer. Oncologist, 8, 335-41.
  8. Campos SM (2004). Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist, 9, 126-36.
  9. Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
  10. Davies C, Godwin J, Gray R, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-84.
  11. Dowsett M, Smith IE, Ebbs SR, et al (2005). Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res, 11, 951-8.
  12. Gruvberger S, Ringner M, Chen Y, et al (2001). Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res, 61, 5979-84.
  13. Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov, 2, 205-13.
  14. Kjellstrand P (1980). Mechanisms of the feulgen acid hydrolysis. J Microscopy, 119, 391-6.
  15. Klotz IM (1982). Numbers of receptor sites from Scatchard graphs: facts and fantasies. Science, 217, 1247-9.
  16. Long BJ, Jelovac D, Handratta V, et al (2004). Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J National Cancer Institute, 96, 456-65.
  17. McGuire WL, Tandon AK, Allred DC, Chamness GC, McClark GM (1990). How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst, 82, 1006-15.
  18. Mouridsen H, Gershanovich M, Sun Y, et al (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol, 21, 2101-9.
  19. Mouridsen HT (2007). Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat, 105, 19-29.
  20. O'Neill M, Paulin FEM, Vendrell J, Ali CW, Thompson AM (2012). The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model. BioDiscovery, 6, 1-8.
  21. Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med, 339, 1609.
  22. Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P (2008). Aromatase inhibitors for breast cancer: different structures, same effects? Endocr Relat Cancer, 15, 27-36.
  23. Santen RJ, Harvey HA (1999). Use of aromatase inhibitors in breast carcinoma. Endocrine-Related Cancers, 6, 75-92.

Cited by

  1. Effects of Metformin on Cell Kinetic Parameters of MCF-7 Breast Cancer Cells in Vitro vol.16, pp.6, 2015,